BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31752769)

  • 1. Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study.
    Yang J; Yuan M; Wang E; Xia S; Chen Y
    BMC Ophthalmol; 2019 Nov; 19(1):237. PubMed ID: 31752769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
    Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
    Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
    Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Kim M; Kim K; Kim DG; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy: Fight Retinal Blindness! Cohort.
    Chong Teo KY; Squirrell DM; Nguyen V; Banerjee G; Cohn A; Barthelmes D; Gemmy Cheung CM; Gillies M
    Ophthalmol Retina; 2019 Mar; 3(3):220-229. PubMed ID: 31014698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.
    Mori R; Tanaka K; Yuzawa M
    Medicine (Baltimore); 2018 Jun; 97(25):e11188. PubMed ID: 29924037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.
    Agorogiannis EI; Pearce IA; Yadav S; Parry DG; Beare NAV
    Eye (Lond); 2018 Nov; 32(11):1731-1739. PubMed ID: 30002485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy.
    Yang J; Yuan M; Xia S; Chen Y
    J Ophthalmol; 2019; 2019():1609717. PubMed ID: 31949949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy.
    Kang HM; Koh HJ
    Ophthalmologica; 2014; 231(2):86-93. PubMed ID: 24135710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
    JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
    Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
    Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
    Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
    Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
    Lee JH; Lee WK
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
    Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
    BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
    Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
    Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.
    Gemmy Cheung CM; Yeo I; Li X; Mathur R; Lee SY; Chan CM; Wong D; Wong TY
    Am J Ophthalmol; 2013 Feb; 155(2):295-304.e1. PubMed ID: 23111181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.